{"id":37179,"date":"2026-03-20T11:06:00","date_gmt":"2026-03-20T15:06:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37179"},"modified":"2026-03-08T14:21:09","modified_gmt":"2026-03-08T18:21:09","slug":"the-complete-guide-to-how-long-drug-patents-last-across-the-commonwealth-of-independent-states-cis","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-complete-guide-to-how-long-drug-patents-last-across-the-commonwealth-of-independent-states-cis\/","title":{"rendered":"The Complete Guide to How Long Drug Patents Last Across the Commonwealth of Independent States (CIS)"},"content":{"rendered":"\n

Why CIS Patent Terms Confuse Even Experienced IP Professionals<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

When a pharmaceutical company’s legal team maps out its global IP strategy, the Commonwealth of Independent States tends to occupy an uncomfortable position: too large to ignore, too fragmented to manage with a single set of rules. The combined pharmaceutical market of the twelve CIS states generates tens of billions of dollars in annual drug sales, Russia alone accounting for more than $20 billion at retail prices [1], yet the IP framework governing those sales involves no fewer than three overlapping legal architectures, twelve national patent laws in various states of harmonization, and a regional treaty organization that grants unitary protection across nine of those countries but leaves three more to operate on entirely national terms.<\/p>\n\n\n\n

The central question – how long does a drug patent last in the CIS? – sounds deceptively simple. The answer depends on whether the patent was filed through the Eurasian Patent Organization (EAPO) or through a national patent office, whether the patent holder obtained a supplementary protection certificate or its local equivalent, which country’s regulatory approval timeline is being used to calculate any extension, whether the country in question has implemented data exclusivity or patent linkage, and whether the government has invoked its compulsory licensing authority in the interim. All of those variables differ across the twelve states, and several of them have changed materially in the past five years.<\/p>\n\n\n\n

This guide is structured for pharmaceutical companies that need to make concrete commercial decisions: whether to file Eurasian or national patents, how much runway their current portfolio has in specific CIS markets, when generic entry becomes legally possible in each country, and how to monitor competitive threats in a region where patent databases are fragmented and English-language intelligence is sparse. Tools like DrugPatentWatch, which aggregates international pharmaceutical patent and exclusivity data from multiple national sources, provide a starting point for the data infrastructure. This guide provides the analytical framework to interpret what that data means.<\/p>\n\n\n\n

\n\n\n\n

The CIS: Membership, Markets, and the Post-Soviet IP Architecture<\/h2>\n\n\n\n

The Twelve Member States and Their Commercial Relevance<\/h3>\n\n\n\n

The Commonwealth of Independent States was established in 1991 following the dissolution of the Soviet Union and initially included eleven of the fifteen former Soviet republics. Georgia joined in 1993 and withdrew in 2009 following the South Ossetia war. The current members are Russia, Ukraine (suspended participation since 2018 though technically still a party to certain treaties), Kazakhstan, Belarus, Azerbaijan, Uzbekistan, Kyrgyzstan, Tajikistan, Turkmenistan, Armenia, and Moldova.<\/p>\n\n\n\n

Their pharmaceutical markets differ enormously in size. Russia generates roughly 60 percent of total CIS pharmaceutical spending. Ukraine, despite its geopolitical disruption, had the second-largest CIS market before 2022, with annual retail pharmaceutical sales of approximately $4 billion [2]. Kazakhstan, with its oil-driven purchasing power, has become the third-largest CIS pharmaceutical market and is increasingly attractive to multinational manufacturers. The remaining eight states are smaller markets, but collectively represent hundreds of millions of dollars in drug sales and, for orphan disease treatments and specialty products, strategically important patient populations.<\/p>\n\n\n\n

The commercial weight of each market determines how much IP protection is worth obtaining. A multinational brand manufacturer might file Eurasian patents covering all nine EAPO member states as a matter of course, but the decision to file and maintain separate national patents in Turkmenistan or Tajikistan requires a market-by-market ROI calculation that many companies perform only superficially.<\/p>\n\n\n\n

The Soviet Legacy: Why IP Law Started From Zero in 1991<\/h3>\n\n\n\n

Soviet law recognized “Author’s Certificates” rather than patents for inventions [3]. Author’s Certificates assigned the invention to the state while granting the inventor a small compensation and recognition. They provided no private exclusionary rights of the type that underpin pharmaceutical patent protection in market economies. When the Soviet Union dissolved, every successor state had to build a patent system essentially from scratch.<\/p>\n\n\n\n

Russia enacted its first post-Soviet Patent Law in 1992 [4]. The other states followed in rapid succession, many of them drawing on Russian drafts with local modifications. The result was a family of patent laws with significant structural similarities – most adopted 20-year patent terms from filing date, most created patent offices modeled on the Russian Patent Office (Rospatent), and most accepted Paris Convention filings – but with enough variation in implementation details to create the fragmented landscape that IP professionals deal with today.<\/p>\n\n\n\n

The speed of this legislative construction created gaps that persisted for years. Data exclusivity for pharmaceutical test data, for example, was not implemented in Russia until 2010 and was not meaningfully enforced until regulatory reforms in 2014 [5]. Several smaller CIS states still have data exclusivity frameworks that are either absent from their national laws or present on paper but unenforced in practice.<\/p>\n\n\n\n

\n\n\n\n

The Eurasian Patent Organization: One Filing, Nine Countries<\/h2>\n\n\n\n

What the EAPO Covers and What It Does Not<\/h3>\n\n\n\n

The Eurasian Patent Convention (EPC) – not to be confused with the European Patent Convention – was signed in 1994 and entered into force in 1995. It established the Eurasian Patent Organization, headquartered in Moscow, with authority to grant unitary patents valid across its member states [6]. The current EAPO member states are Russia, Kazakhstan, Belarus, Armenia, Kyrgyzstan, Tajikistan, Azerbaijan, Turkmenistan, and Moldova.<\/p>\n\n\n\n

Ukraine is not an EAPO member, despite being a CIS state. Uzbekistan left the EAPO in 2012, making its own national patent office the sole route to protection in that market. Georgia, which left the CIS, is also not an EAPO member. These exclusions are commercially significant: Ukraine was historically the second-largest CIS pharmaceutical market, and Uzbekistan’s 35 million population makes it the most populous non-EAPO CIS state.<\/p>\n\n\n\n

A Eurasian patent granted by the EAPO takes effect in all nine member states simultaneously. Maintenance fees are paid centrally to the EAPO and distributed to member states according to an internal protocol. Claims are examined once and the same claim set applies in all member states. This produces real administrative efficiency relative to filing separately in nine national patent offices, but it also means that a successful challenge to a Eurasian patent – through the EAPO’s limited opposition procedures or through national court proceedings in any member state – can potentially affect the patent’s status across all nine countries.<\/p>\n\n\n\n

The 20-Year Eurasian Patent Term<\/h3>\n\n\n\n

Article 3 of the Eurasian Patent Convention establishes a patent term of 20 years from the international filing date [7]. This mirrors the TRIPS Agreement minimum standard and aligns with the term used by the USPTO and the European Patent Office. The starting point is the date of filing the Eurasian patent application, not the date of grant, which typically arrives several years later given the EAPO’s examination timelines.<\/p>\n\n\n\n

For pharmaceutical applications, the average time from Eurasian filing to grant has run approximately 3 to 5 years in recent years, with complex cases taking longer. This means that a drug compound patent filed on the day of first European clinical trials might grant with only 15-17 years of nominal term remaining – and the actual exclusivity period is shorter still, because the drug will not reach the Eurasian market until regulatory approval is obtained, which may follow the filing date by 8 to 12 years for novel compounds.<\/p>\n\n\n\n

The remaining effective patent life for a typical innovative small-molecule drug in EAPO-member markets has historically been 5 to 8 years at the time of first regulatory approval, absent any term extension mechanism. This is the pharmaceutical patent cliff in its most direct form, and it is shorter in the CIS than in the United States, where Patent Term Extension under 35 U.S.C. \u00a7 156 can add up to five years.<\/p>\n\n\n\n

Patent Term Extension in the Eurasian System<\/h3>\n\n\n\n

The EAPO itself does not provide a patent term extension mechanism equivalent to the USPTO’s Patent Term Extension or the EU’s Supplementary Protection Certificate [8]. This is a material deficiency relative to Western systems. In the European Union, an SPC can effectively extend pharmaceutical patent protection for up to five years (plus an additional six-month extension for pediatric investigation), allowing branded manufacturers to recover some of the patent life consumed by regulatory review. The Eurasian system has no equivalent at the regional level.<\/p>\n\n\n\n

Several individual EAPO member states have enacted national-level extensions or supplementary protection mechanisms that apply to Eurasian patents in their territories. Russia’s mechanism is the most developed and commercially significant. But because these national mechanisms vary in their eligibility criteria, calculation methods, and enforcement history, a Eurasian patent holder cannot assume that term extension in Russia translates into equivalent protection in Kazakhstan or Belarus.<\/p>\n\n\n\n

\n\n\n\n

Country-by-Country Patent Term Analysis<\/h2>\n\n\n\n

Russia<\/h3>\n\n\n\n

The 20-Year Base Term and FIPS Administration<\/h4>\n\n\n\n

Russia’s current patent law is Federal Law No. 316-FZ of December 30, 2008, as amended, incorporated within Part IV of the Civil Code of the Russian Federation [9]. Patent rights for inventions – the category that covers pharmaceutical compounds, formulations, and methods of treatment – run 20 years from the filing date of the application at the Federal Institute of Industrial Property (FIPS, known in Russian as Rospatent).<\/p>\n\n\n\n

For Eurasian patents designating Russia, the 20-year term runs from the international filing date of the Eurasian application, and Russia accepts the Eurasian grant as equivalent to a national patent for most purposes. Both national Russian patents and Eurasian patents designating Russia appear in Russia’s patent database, which Rospatent maintains and makes partially accessible online.<\/p>\n\n\n\n

Annual maintenance fees are required to keep patents in force. Russian maintenance fees are relatively modest compared to Western systems, but they escalate over the patent term. A patent allowed to lapse for non-payment of maintenance fees can sometimes be restored within a grace period, but the restoration procedure involves filing with Rospatent and paying arrears, and there is no guarantee of restoration if the lapse period is prolonged.<\/p>\n\n\n\n

Russia’s Supplementary Protection Certificate: The 5-Year Extension<\/h4>\n\n\n\n

Russia introduced a supplementary protection certificate (SPC) mechanism in 2002, amended most recently in 2014 [10]. Under Article 1363 of the Civil Code, the term of a patent on a pharmaceutical compound can be extended for a period equal to the interval between the filing date of the patent application and the date of first marketing authorization for the drug in Russia, minus five years. The maximum extension granted cannot exceed five years.<\/p>\n\n\n\n

To be eligible for an SPC in Russia, four conditions must be met:<\/p>\n\n\n\n

The patent must be a “utility patent” for an invention (not a utility model), covering the active compound or the compound in combination with another agent.<\/p>\n\n\n\n

The drug must have received Russian marketing authorization, issued by the Ministry of Health through Roszdravnadzor, Russia’s pharmaceutical regulator.<\/p>\n\n\n\n

The first marketing authorization in Russia must have been issued more than five years after the patent’s filing date.<\/p>\n\n\n\n

The SPC application must be filed at FIPS within six months of either the marketing authorization date or the patent grant date, whichever is later.<\/p>\n\n\n\n

The practical effect is that Russian pharmaceutical patents on commercially important drugs often carry 3 to 5 extra years of protection beyond the nominal 20-year term, bringing total effective protection closer to the 25-year ceiling that Western SPC systems also target. For major branded drugs that received Russian regulatory approval several years after filing, the full five-year extension is common.<\/p>\n\n\n\n

Russia’s SPC system has been used extensively by multinational pharmaceutical manufacturers to extend exclusivity on high-revenue compounds. The FIPS database records granted SPCs, and DrugPatentWatch’s international patent data integrates Russian SPC information where publicly available, allowing analysts to identify which products benefit from extended terms and when those extended terms expire.<\/p>\n\n\n\n

Data Exclusivity in Russia<\/h4>\n\n\n\n

Russia’s data exclusivity framework, established under the Federal Law on Circulation of Medicines (Federal Law No. 61-FZ, 2010) and regulations implementing it [11], provides six years of data exclusivity for innovative drugs that received marketing authorization after registering clinical trial data with the Russian regulatory authority. During this period, a generic manufacturer cannot use the originator’s clinical trial data to support its own registration application.<\/p>\n\n\n\n

The six-year period runs from the date of the drug’s Russian marketing authorization, not from the global first approval date. This means that a drug approved in the United States in 2015 and in Russia in 2018 would have its Russian data exclusivity expire in 2024, regardless of any patent term remaining. Conversely, Russian data exclusivity can provide protection even after a patent expires or is invalidated, because it operates independently of patent status.<\/p>\n\n\n\n

Russia’s implementation of data exclusivity has been inconsistent. The Federal Antimonopoly Service (FAS) and the Ministry of Health have periodically taken positions that narrow data exclusivity protection in the context of generic registration review, and enforcement against unauthorized reliance on originator data has required active monitoring and legal action by brand manufacturers. The practical value of Russian data exclusivity is real but needs to be monitored through local counsel, not assumed to operate automatically.<\/p>\n\n\n\n

Compulsory Licensing: Russia’s Record<\/h4>\n\n\n\n

Russia has invoked compulsory licensing authority for pharmaceutical patents twice with significant commercial consequences. In 2016, the Russian government issued a compulsory license for sofosbuvir (Gilead’s hepatitis C treatment marketed as Sovaldi) to enable domestic production of affordable generic versions for Russian patients [12]. The decision was made under Article 1360 of the Civil Code, which allows the government to use a patented invention for state needs without the patent holder’s consent, subject to payment of compensation.<\/p>\n\n\n\n

In 2022, following Western sanctions imposed in connection with the Ukraine conflict, Russia’s government greatly expanded the compulsory licensing framework. Government Decree No. 299 of March 6, 2022 authorized the use of patents held by “unfriendly country” residents without compensation, covering patents from the European Union, the United States, the United Kingdom, and other sanctioning states [13]. This decree represented a categorical departure from TRIPS-compliant compulsory licensing procedures, which require case-by-case determinations and reasonable compensation, rather than blanket authorization by country of origin.<\/p>\n\n\n\n

The practical implications for Western pharmaceutical patent holders in Russia are severe. Any patent held by a U.S. or EU entity covering a drug sold or produced in Russia may be exploited without authorization under this framework. Patent expiration dates in Russia are analytically relevant for normal commercial planning, but brand manufacturers holding relevant patents need to factor in the compulsory licensing environment when modeling Russian revenue and IP value.<\/p>\n\n\n\n

Patent Linkage in Russia<\/h4>\n\n\n\n

Russia does not have a formal patent linkage system equivalent to the U.S. Hatch-Waxman framework, where generic drug registration approval is administratively connected to patent status [14]. A generic manufacturer in Russia can file a registration application for a drug regardless of whether the originator’s patent is in force. The patent does not block registration approval; it only provides a cause of action for patent infringement after the generic is marketed.<\/p>\n\n\n\n

This absence of patent linkage means that brand manufacturers in Russia receive no automatic 30-month stay analogous to U.S. Paragraph IV litigation. Generic entry is possible as soon as the generic company obtains registration and patent infringement litigation must be pursued separately and reactively. Several international pharmaceutical companies have lobbied for Russian patent linkage through bilateral trade discussions, with limited practical result to date.<\/p>\n\n\n\n

Ukraine<\/h3>\n\n\n\n

The Ukrainian Patent System After Conflict<\/h4>\n\n\n\n

Ukraine’s patent system is administered by the Ukrainian Intellectual Property Institute (Ukrpatent). The country’s basic patent term is 20 years from filing, consistent with its obligations as a TRIPS member [15]. Ukraine became a WTO member in 2008 and has been required to maintain TRIPS-compliant IP protection since accession.<\/p>\n\n\n\n

Ukraine’s pharmaceutical patent landscape has been materially disrupted by the ongoing armed conflict that began with Russia’s full-scale invasion in February 2022. Patent prosecution, maintenance fee payments, and IP enforcement have all been affected by the security environment, disruptions to state institutions, and mass displacement of population. The Ukrainian government has enacted force majeure provisions allowing certain IP deadlines to be suspended or extended during the conflict period, but the practical functioning of the IP system in conflict-affected areas has been severely impaired.<\/p>\n\n\n\n

Before 2022, Ukraine was the second-largest pharmaceutical market among CIS states, with a branded drug sector that was commercially significant for multinational manufacturers. The pre-conflict data exclusivity framework provided six years of protection for pharmaceutical test data from the date of Ukrainian marketing authorization [16]. Whether this framework functions reliably under current conditions is a question requiring real-time assessment, and brand manufacturers should treat Ukrainian IP protection as subject to heightened uncertainty until the legal and institutional environment stabilizes.<\/p>\n\n\n\n

Ukraine’s Non-EAPO Status: The Filing Requirement<\/h4>\n\n\n\n

Because Ukraine is not a member of the EAPO, pharmaceutical companies seeking patent protection in Ukraine must file national patent applications at Ukrpatent. A Eurasian patent provides no protection in Ukraine. This creates a two-track filing requirement for companies seeking both Ukrainian and EAPO-member protection: a Eurasian application for the nine EAPO states, and a separate Ukrainian national application.<\/p>\n\n\n\n

Ukrainian national applications can be filed through the Patent Cooperation Treaty (PCT) route with Ukraine designated as a national phase country, or through a direct national filing at Ukrpatent. Given the current security environment, many multinational companies have suspended new Ukrainian filings or are filing defensively without actively prioritizing prosecution timelines.<\/p>\n\n\n\n

For patent term calculation purposes, Ukraine’s 20-year term from filing runs independently of the EAPO patent term. A drug with an EAPO patent expiring in 2030 may have a Ukrainian patent expiring earlier or later depending on the separate Ukrainian filing date. Mapping both timelines is essential for accurate assessment of CIS market protection.<\/p>\n\n\n\n

Kazakhstan<\/h3>\n\n\n\n

Kazakhstan’s Dual-Track Patent System<\/h4>\n\n\n\n

Kazakhstan, the largest landlocked country in the world by area and the wealthiest CIS state by per capita income after Russia, has become an increasingly important pharmaceutical market. The government’s health spending and a growing middle class have pushed branded drug consumption higher, and Kazakhstan’s regulatory authority (the Ministry of Healthcare, with registration administered through the National Center for Expertise of Drugs) has streamlined its approval processes in recent years.<\/p>\n\n\n\n

Kazakhstan is an EAPO member, so Eurasian patents provide protection in Kazakhstan without separate national filing. The 20-year Eurasian patent term applies. Separately, Kazakhstan maintains a national patent office (the National Institute of Intellectual Property, NIIP) that processes applications for inventions not filed through the EAPO, and Kazakhstani inventors frequently file national applications as a complement to Eurasian filings.<\/p>\n\n\n\n

Kazakhstan has not enacted a patent term extension mechanism comparable to Russia’s SPC system [17]. The 20-year Eurasian term, plus any Russian SPC that runs in Russia only, governs the patent landscape. Data exclusivity for pharmaceutical test data was introduced in Kazakhstan as part of its WTO accession process (Kazakhstan joined the WTO in 2015) and the implementing regulations provide five years of protection from marketing authorization date, shorter than Russia’s six-year period.<\/p>\n\n\n\n

The EAEU Drug Registration Route<\/h4>\n\n\n\n

Kazakhstan is a member of the Eurasian Economic Union (EAEU) along with Russia, Belarus, Armenia, and Kyrgyzstan. The EAEU has been developing a unified drug registration system under which a single EAEU-wide registration would grant marketing authorization across all five member states. This initiative, based on the Common Market of Medicinal Products agreement signed in 2016 [18], directly affects how pharmaceutical companies interact with the regulatory landscape in these five countries.<\/p>\n\n\n\n

From a patent perspective, the EAEU registration route does not change patent terms, which remain governed by national patent laws and the EAPO Convention. But it does affect data exclusivity timelines, since EAEU regulations are harmonizing how data exclusivity periods are calculated and what data qualifies for protection. The interaction between EAEU-wide marketing authorizations and national data exclusivity periods is still being worked out in practice, and companies planning multi-country launches in EAEU markets should verify current regulatory guidance rather than assuming national rules apply unchanged.<\/p>\n\n\n\n

Belarus<\/h3>\n\n\n\n

Belarus is an EAPO member with a 20-year patent term. Its national patent office (the National Center of Intellectual Property, NCIP) also processes national applications, and Belarusian national patents on inventions run 20 years from filing [19]. Belarus’s pharmaceutical market is relatively small but distinctive because of its heavily state-controlled healthcare system, which makes government procurement and pricing decisions particularly significant for branded drug commercial viability.<\/p>\n\n\n\n

Belarus has not enacted a standalone patent term extension system. Data exclusivity, introduced following Belarus’s TRIPS obligations, provides five years of protection for pharmaceutical test data from marketing authorization. Like Russia, Belarus lacks formal patent linkage, meaning generic registration is not administratively blocked by patent status.<\/p>\n\n\n\n

Belarus’s geopolitical alignment with Russia following the 2022 developments means its IP enforcement environment has tracks roughly parallel to Russia’s for Western patent holders: the theoretical framework for protection exists, but the practical enforceability of patents held by Western entities against Belarusian generic manufacturers or state-controlled competitors requires active monitoring. Belarusian courts have historically been less experienced with complex pharmaceutical patent litigation than Russian courts, and the track record for multinational plaintiff success is thinner.<\/p>\n\n\n\n

Azerbaijan<\/h3>\n\n\n\n

Azerbaijan’s National Intellectual Property Agency (COPAT) administers a patent system with a 20-year term from filing [20]. Azerbaijan is an EAPO member, and Eurasian patents provide protection there without separate national filing. The Azerbaijani pharmaceutical market has grown alongside hydrocarbon-driven economic development and is among the more commercially relevant smaller CIS markets for specialty and branded drugs.<\/p>\n\n\n\n

Azerbaijan’s TRIPS-required data exclusivity period is five years from marketing authorization. There is no patent term extension mechanism in Azerbaijan. Patent enforcement proceedings are conducted in Azerbaijani courts, which have limited experience with complex pharmaceutical patent cases. Brand manufacturers with Azerbaijani sales have generally relied on Eurasian patents for primary protection and have supplemented this with careful monitoring of generic registration filings at COPAT and the Ministry of Health.<\/p>\n\n\n\n

Georgia<\/h3>\n\n\n\n

Georgia formally withdrew from the CIS in 2009 following the South Ossetia conflict, and is not an EAPO member, requiring separate national filings at the Georgian National Intellectual Property Center (Sakpatenti). Georgia’s patent term is 20 years from filing, consistent with TRIPS requirements [21]. Georgia joined the WTO in 2000 and has maintained a functional IP framework since, including five years of data exclusivity for pharmaceutical test data.<\/p>\n\n\n\n

Georgia’s proximity to EU markets and its Association Agreement with the European Union have driven regulatory reforms that bring Georgian pharmaceutical IP law progressively closer to European standards. Pharmaceutical companies with European patent strategies sometimes include Georgia in their PCT filings for completeness, though the market size is small relative to the filing and maintenance cost.<\/p>\n\n\n\n

Uzbekistan<\/h3>\n\n\n\n

Uzbekistan’s exit from the EAPO in 2012 requires separate national filings at the Uzbek Agency for Intellectual Property (Uzpatent) for protection there. Uzbekistan’s patent term is 20 years from filing [22]. With approximately 35 million people, Uzbekistan is the most populous post-Soviet state after Russia and Ukraine, and its pharmaceutical market has been growing rapidly as economic reforms under President Shavkat Mirziyoyev have opened the economy to more private sector activity.<\/p>\n\n\n\n

Uzbekistan’s data exclusivity framework was strengthened following its WTO observer status negotiations and provides six years of protection from the date of marketing authorization in Uzbekistan [23]. A drug approved in Uzbekistan in 2020 benefits from data exclusivity running to 2026, independently of patent status. There is no Uzbek patent term extension mechanism.<\/p>\n\n\n\n

The administrative competence of Uzpatent has improved over the past decade, but PCT national phase filings into Uzbekistan still encounter longer prosecution timelines than in EAPO proceedings. For companies that exited the EAPO system before Uzbekistan’s departure, post-2012 pipeline compounds require active national filing decisions that were not necessary under the prior unified system.<\/p>\n\n\n\n

Armenia<\/h3>\n\n\n\n

Armenia is an EAPO member with a 20-year patent term. Its Intellectual Property Agency administers national applications. Armenia joined the EAEU in 2015, bringing it within the harmonization framework for drug registration and data exclusivity [24].<\/p>\n\n\n\n

Armenia’s pharmaceutical market is small by absolute measures but notable for its comparatively well-functioning IP enforcement system relative to several of its CIS peers. Armenian courts have handled pharmaceutical patent cases with greater procedural predictability than is typical for some of the Central Asian EAPO members, making Armenia a useful test case for how the EAPO patent enforcement environment functions in practice.<\/p>\n\n\n\n

Moldova<\/h3>\n\n\n\n

Moldova is an EAPO member that has simultaneously pursued EU Association Agreement status and adopted aspects of European IP harmonization. Moldova’s patent term is 20 years from filing, and the State Agency on Intellectual Property (AGEPI) administers national applications [25].<\/p>\n\n\n\n

Moldova’s data exclusivity framework aligns more closely with the EU model than with the CIS norm, providing eight years of data exclusivity for novel pharmaceutical compounds (equivalent to the “8+2+1” structure in EU law), a notably longer period than the five or six years typical of other CIS states. Moldova’s EU Association Agreement, signed in 2014, has driven regulatory convergence that benefits brand manufacturers seeking extended protection in that market.<\/p>\n\n\n\n

Moldova’s market is small, but its data exclusivity outlier status makes it a country worth identifying separately in any CIS portfolio analysis. A drug whose data exclusivity has lapsed in Russia and Kazakhstan may still enjoy data exclusivity protection in Moldova if the Moldovan marketing authorization was obtained more recently.<\/p>\n\n\n\n

Kyrgyzstan, Tajikistan, and Turkmenistan<\/h3>\n\n\n\n

These three smaller Central Asian EAPO members share similar patent structures: 20-year terms from filing, no patent term extension mechanisms, and data exclusivity periods of five years from marketing authorization, enacted as a result of their TRIPS obligations [26, 27, 28].<\/p>\n\n\n\n

Kyrgyzstan joined the EAEU in 2015, bringing it into the EAEU harmonization framework. Tajikistan and Turkmenistan are not EAEU members and have maintained more independent regulatory paths.<\/p>\n\n\n\n

Enforcement capacity in all three countries is limited. Pharmaceutical patent litigation in these markets has been rare, not because infringement does not occur but because the economic stakes for branded manufacturers are often too small to justify active litigation, and because local court systems lack experience with the technical complexity of pharmaceutical patent cases. Brand manufacturers with products in these markets often rely on administrative procedures – monitoring generic registrations and objecting to improperly listed or data-protected drugs at the health ministry level – rather than court-based patent enforcement.<\/p>\n\n\n\n

For patent term calendar purposes, Eurasian patents designating these countries expire on the same date as the Eurasian grant, since none of these countries has a mechanism to extend the term at the national level. The effective exclusivity period is the 20-year Eurasian term minus prosecution time, which is the same calculation used for Russia and other EAPO members without SPCs.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Exclusivity vs. Patent Protection: The Critical Distinction<\/h2>\n\n\n\n

Why the Two Systems Must Be Analyzed Together<\/h3>\n\n\n\n

Pharmaceutical exclusivity in the CIS, as in Western markets, is a product of two distinct legal systems that operate independently but interact commercially. Patent protection is granted by patent offices, runs from patent filing dates, and is enforced through civil litigation. Regulatory exclusivity is granted by health ministries based on marketing authorization data, runs from regulatory approval dates, and is enforced through the drug registration system.<\/p>\n\n\n\n

A drug can lose its patent protection while retaining regulatory data exclusivity. It can also have an active patent but expired data exclusivity. Understanding the cliff date for any specific drug in any specific CIS market requires mapping both systems and identifying which one controls competitive entry in the relevant time window. <blockquote> “According to the World Health Organization’s 2023 pharmaceutical pricing and access report, data exclusivity periods in upper-middle-income countries – a category that includes several CIS states – typically delay generic market entry by 3 to 6 years beyond the regulatory review period alone, independent of any patent protection in force.” [29] <\/blockquote><\/p>\n\n\n\n

Data Exclusivity Periods by Country: The Comparison Table<\/h3>\n\n\n\n

The data exclusivity landscape across CIS states, summarized:<\/p>\n\n\n\n

Russia: 6 years from Russian marketing authorization date, under Federal Law No. 61-FZ as amended. This is among the longer periods in the CIS and reflects Russia’s negotiating position in WTO accession discussions.<\/p>\n\n\n\n

Ukraine: 6 years from Ukrainian marketing authorization, pre-conflict framework under Law of Ukraine No. 2469-VIII (2018) amending the Law on Medicinal Products. Current enforceability is subject to conflict-related institutional disruption.<\/p>\n\n\n\n

Kazakhstan: 5 years from Kazakhstani marketing authorization, under the Code of the Republic of Kazakhstan on Public Health and the Healthcare System (2020 edition).<\/p>\n\n\n\n

Belarus: 5 years from Belarusian marketing authorization, under the Law on Medicines (2008, as amended).<\/p>\n\n\n\n

Moldova: 8 years from Moldovan marketing authorization, aligned with EU framework under the EU-Moldova Association Agreement implementing legislation – the longest data exclusivity period in the CIS region.<\/p>\n\n\n\n

Azerbaijan, Armenia, Kyrgyzstan: 5 years from national marketing authorization.<\/p>\n\n\n\n

Uzbekistan: 6 years from Uzbek marketing authorization.<\/p>\n\n\n\n

Tajikistan, Turkmenistan: 5 years from national marketing authorization, though enforcement infrastructure is limited.<\/p>\n\n\n\n

Georgia: 5 years from Georgian marketing authorization, under the Law on Medicines (2009, as amended).<\/p>\n\n\n\n

Orphan Drug and Pediatric Provisions in the CIS<\/h3>\n\n\n\n

Russia is the only CIS state that has enacted dedicated orphan drug legislation with IP implications. Federal Law No. 61-FZ (2010) and the subsequent List of Rare (Orphan) Diseases created a framework for orphan drug designation and extended data exclusivity for drugs designated for rare diseases – providing ten years of data exclusivity rather than the standard six years, for drugs approved for conditions affecting fewer than 10 people per 100,000 of Russian population [30].<\/p>\n\n\n\n

This ten-year orphan exclusivity is commercially significant for manufacturers of rare disease treatments in Russia. Combined with patent protection, it can produce effective market exclusivity extending well past the 20-year patent cliff. A company whose compound patent expires in 2026 but whose orphan drug designation provides data exclusivity through 2033 has a seven-year window in which generic entry is blocked by regulatory exclusivity even after patent expiration.<\/p>\n\n\n\n

Kazakhstan has introduced orphan drug designation under its 2020 Public Health Code but has not yet implemented longer data exclusivity periods for orphan products. The other CIS states lack formal orphan drug IP provisions, though several have ad hoc regulatory mechanisms that achieve similar practical results through pricing and reimbursement policies.<\/p>\n\n\n\n

Pediatric exclusivity extensions analogous to the U.S. Hatch-Waxman six-month pediatric exclusivity or the EU’s six-month SPC extension for pediatric investigation do not exist in any CIS state, including Russia. This gap means that the incentive structure for pediatric drug development in CIS markets is weaker than in Western markets.<\/p>\n\n\n\n

\n\n\n\n

Generic Entry Mechanisms in CIS Markets<\/h2>\n\n\n\n

How CIS Generics Get to Market<\/h3>\n\n\n\n

Generic drug market entry in CIS countries follows a regulatory path broadly analogous to Western generic approval systems, but with significant procedural differences. There is no CIS-wide Abbreviated New Drug Application (ANDA) equivalent. Each country administers its own generic registration process, which typically requires bioequivalence studies demonstrating that the generic product is equivalent to the reference drug, along with chemistry, manufacturing, and controls documentation.<\/p>\n\n\n\n

Russia’s generic approval process, administered by Roszdravnadzor, has become more rigorous over the past decade. Russian regulations now require bioequivalence studies conducted in Russia or in jurisdictions whose studies Russia accepts, a requirement that effectively mandates additional clinical work for generic manufacturers who did not conduct original studies domestically [31]. The time from generic application filing to approval in Russia runs approximately 18 to 30 months, a timeline that affects how quickly generic competition materializes after patent and exclusivity expiry.<\/p>\n\n\n\n

Kazakhstan, Belarus, and other EAEU members are converging toward a unified bioequivalence standard under EAEU regulations, which should harmonize generic approval requirements across those five states over time. Until that harmonization is complete, generic manufacturers targeting multiple EAEU markets must navigate both national and emerging union-level requirements simultaneously.<\/p>\n\n\n\n

The Absence of Formal Patent Linkage and What It Means Commercially<\/h3>\n\n\n\n

None of the major CIS pharmaceutical markets has implemented formal patent linkage comparable to the U.S. Hatch-Waxman system, in which a generic application for a patented drug automatically triggers a notification to the patent holder and a mandatory waiting period before generic approval [14]. Russia, Kazakhstan, Belarus, Ukraine, and the other CIS states all allow generic drug applications to proceed through registration independent of patent status.<\/p>\n\n\n\n

For brand manufacturers, this creates a specific monitoring requirement. Because generic registration does not trigger automatic patent holder notification, brand manufacturers must actively monitor generic registration applications filed with health ministries to identify potential infringing products before they reach the market. Russia publishes pending registration applications in a State Register of Medicines that is publicly accessible, allowing brand manufacturers or their monitoring services to track generic filings by active ingredient.<\/p>\n\n\n\n

Several Eastern European states that are not CIS members – notably Poland and the Czech Republic – have demonstrated that patent linkage can be implemented in post-Communist legal systems without fundamental structural change. The EAEU’s ongoing pharmaceutical harmonization discussions have included proposals for a patent linkage mechanism at the union level, but as of the time of writing, no formal proposal has advanced to implementation [32].<\/p>\n\n\n\n

In the absence of linkage, the practical enforcement tool available to brand manufacturers is preliminary injunction practice in Russian and other CIS courts. A brand manufacturer that identifies a generic registration application can seek a preliminary injunction blocking the generic from commercializing the product after approval, pending a full patent validity and infringement determination. Russian courts have granted preliminary injunctions in pharmaceutical patent cases, including several notable cases involving HIV antiretroviral drugs in the 2010s, but the speed and reliability of this remedy varies across CIS jurisdictions.<\/p>\n\n\n\n

Compulsory Licenses: The CIS Framework<\/h3>\n\n\n\n

Russia’s Compulsory License Record and Post-2022 Expansion<\/h4>\n\n\n\n

Russia’s use of compulsory licensing authority before 2022 was consistent with TRIPS Article 31 requirements: individual, case-by-case authorizations for specific drugs, supported by a public health rationale and subject to reasonable compensation [33]. The 2016 sofosbuvir compulsory license, referenced above, was the most prominent example and followed a documented pricing and access dispute between Gilead Sciences and Russian health authorities.<\/p>\n\n\n\n

The 2022 Decree No. 299 categorically changed this framework. By authorizing patent use without compensation for patents held by “unfriendly country” nationals – a designation covering essentially all Western pharmaceutical innovators – Russia moved outside the TRIPS framework entirely. TRIPS Article 31(h) requires that the patent holder receive adequate remuneration, and a blanket exclusion by country of origin does not satisfy that requirement [34].<\/p>\n\n\n\n

The practical commercial consequence is that a Russian generic manufacturer that wishes to produce a patented Western drug can now do so without licensing, without the compensation process, and without the individual authorization that TRIPS requires. Russia’s withdrawal from TRIPS compliance does not automatically make the compulsory licenses internationally unenforceable, but it does affect the compensation that brand manufacturers can realistically expect to receive for Russian market use of their patents.<\/p>\n\n\n\n

Kazakhstan’s Compulsory License Cases<\/h4>\n\n\n\n

Kazakhstan’s government has invoked compulsory licensing authority more selectively than Russia, but has done so in several documented instances involving antiretrovirals for HIV treatment and hepatitis C therapies. Kazakhstan’s Patent Law permits the government to grant compulsory licenses for public health reasons in conformity with TRIPS Article 31, with compensation to the patent holder determined by a government commission [35].<\/p>\n\n\n\n

The practical effect of Kazakhstani compulsory licenses has been to enable local generic production or importation of lower-cost versions of patented drugs for the national health system’s procurement. Brand manufacturers affected by Kazakhstani compulsory licenses have generally focused their responses on the compensation negotiation process rather than international dispute resolution, given the cost and complexity of WTO dispute proceedings relative to the market size.<\/p>\n\n\n\n

Belarus, Azerbaijan, and Other Member States<\/h4>\n\n\n\n

Belarus has compulsory licensing authority in its Patent Law consistent with TRIPS requirements but has used it rarely in the pharmaceutical context. Azerbaijan’s compulsory licensing framework has similarly seen limited pharmaceutical sector application. The smaller Central Asian states have the legal authority for compulsory licensing but the combination of small market size and limited domestic generic manufacturing capacity has meant that compulsory licensing as a practical competitive tool is less relevant there than in Russia or Kazakhstan.<\/p>\n\n\n\n

\n\n\n\n

Eurasian Patent vs. National Patent: The Filing Strategy Decision<\/h2>\n\n\n\n

The Cost-Benefit Calculation<\/h3>\n\n\n\n

Filing a Eurasian patent application through the EAPO covers nine countries for official fees that are lower than filing separately in those nine national patent offices. The 2024 EAPO filing fee schedule has the search and examination fees for a single Eurasian application running approximately EUR 2,000 to 4,000 depending on application complexity [36], compared to the aggregate cost of separate national filings in Russia, Kazakhstan, Belarus, Armenia, Azerbaijan, Kyrgyzstan, Tajikistan, Turkmenistan, and Moldova.<\/p>\n\n\n\n

Annual maintenance fees for a Eurasian patent are paid to the EAPO and distributed to member states. Maintaining a Eurasian patent in all nine member states costs more than maintaining it in only one state, but less than the aggregate of nine separate national maintenance schedules. For companies with significant commercial presence across multiple EAPO states, the Eurasian route generates real cost savings over the 20-year patent term.<\/p>\n\n\n\n

The tradeoff is flexibility. A Eurasian patent has a single claim set that applies across all nine member states. If the claims need to be modified during prosecution to overcome prior art, the modification applies universally. A validity challenge in one member state can, in some circumstances, affect the patent’s status in others, since Russian courts that invalidate a Eurasian patent in Russia may in practice undermine the patent’s enforceability in smaller member states that follow Russian jurisprudence.<\/p>\n\n\n\n

When National Filing Is Preferred<\/h3>\n\n\n\n

There are four scenarios in which national filing over EAPO is strategically preferable:<\/p>\n\n\n\n

When the commercial value is concentrated in one or two specific EAPO member states, and the cost of maintaining broader Eurasian coverage is not justified by revenue projections in smaller states.<\/p>\n\n\n\n

When claim scope optimization is important and the applicant wants different claim sets in different markets, reflecting local prior art or local regulatory treatment of certain claim types.<\/p>\n\n\n\n

When the applicant needs to pursue divisional applications in specific markets, since the EAPO’s divisional application procedures are less flexible than national systems in some respects.<\/p>\n\n\n\n

When the Eurasian patent system’s examination quality or prosecution timeline is creating delays that would be avoided through direct national filing, particularly in Russia where national prosecution has sometimes been faster for specific technology areas.<\/p>\n\n\n\n

For Ukraine, Uzbekistan, and Georgia – the three non-EAPO CIS states – there is no Eurasian option at all, and national filing decisions must be made separately. Given the commercial significance of Ukraine and Uzbekistan, these decisions typically involve active analysis of the local market opportunity against the cost of separate prosecution and maintenance.<\/p>\n\n\n\n

The PCT Route Into EAPO and National Systems<\/h3>\n\n\n\n

Most pharmaceutical companies file PCT international applications as the first step in pursuing international patent protection. The PCT filing preserves the option to pursue national or regional phase filings in designated countries for 30 months from the priority date, allowing time to assess commercial development data before committing to the cost of national phase entry.<\/p>\n\n\n\n

For CIS countries, PCT international applications can designate the EAPO as a regional office (covering all nine EAPO member states), Ukraine as a national phase country, Uzbekistan as a national phase country, and Georgia as a national phase country. A single PCT application can therefore preserve filing rights across all major CIS markets, with the decision about which national or regional filings to pursue deferred until the 30-month deadline.<\/p>\n\n\n\n

The 30-month PCT deadline creates a specific action point in every pharmaceutical company’s patent prosecution calendar. For drugs that show clinical promise by the 30-month point, entering EAPO and major national phases is straightforward. For drugs still in early development, companies must decide whether to extend prosecution under the 31-month national phase rules available in some jurisdictions, or to let certain country designations lapse.<\/p>\n\n\n\n

\n\n\n\n

TRIPS Compliance and International Trade Law Context<\/h2>\n\n\n\n

CIS States’ TRIPS Obligations<\/h3>\n\n\n\n

All CIS states except Turkmenistan are WTO members and therefore bound by the Agreement on Trade-Related Aspects of Intellectual Property Rights [37]. Turkmenistan is not a WTO member and is technically not bound by TRIPS standards, though its patent law largely tracks the standards of neighboring EAPO member states.<\/p>\n\n\n\n

TRIPS Article 27 requires member states to make patents available for any inventions in all fields of technology, including pharmaceutical compounds. Article 33 requires a minimum 20-year patent term from filing. Article 39 requires protection of undisclosed test data submitted to regulatory authorities – the basis for data exclusivity regimes. These obligations form the floor of pharmaceutical IP protection that CIS WTO members cannot fall below.<\/p>\n\n\n\n

Russia’s post-2022 approach to Western pharmaceutical patents – authorization without compensation under Decree No. 299 – is a TRIPS violation if it is applied to pharmaceutical patents held by TRIPS-member nationals. The WTO’s dispute settlement mechanism could, in theory, be used by affected countries to challenge Russia’s practice. In the current geopolitical environment, the United States and European Union have not pursued WTO dispute proceedings against Russia’s compulsory licensing practice, prioritizing other retaliatory mechanisms.<\/p>\n\n\n\n

Ukraine’s constitution and domestic law incorporate TRIPS obligations, and its dispute settlement rights as a WTO member are not affected by its CIS status or the ongoing conflict. Ukrainian manufacturers or government entities that infringe pharmaceutical patents held by foreign nationals could face WTO dispute proceedings pursued by the patent holder’s home country, independent of the bilateral Russia-Ukraine conflict.<\/p>\n\n\n\n

EAEU Pharmaceutical Harmonization and IP Convergence<\/h3>\n\n\n\n

The Eurasian Economic Union’s five members – Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan – have been working to harmonize pharmaceutical regulation under the Common Market of Medicinal Products framework since 2016 [38]. IP elements of this harmonization include:<\/p>\n\n\n\n

Alignment of data exclusivity periods, with an EAEU-level minimum standard being discussed that would set a floor applicable across all five member states.<\/p>\n\n\n\n

Development of a common reference drug list that defines which drugs qualify as reference products for generic bioequivalence testing and data exclusivity purposes.<\/p>\n\n\n\n

Consideration of a patent linkage mechanism at the EAEU level, which would create an administrative connection between drug registration and patent status for the first time in any of the five EAEU markets.<\/p>\n\n\n\n

Progress on these EAEU harmonization initiatives has been slow, and the political disruptions since 2022 have complicated the institutional functioning of EAEU bodies. But the trajectory toward greater harmonization means that pharmaceutical IP analysts should monitor EAEU regulatory developments as a leading indicator of how national rules may change across those five markets.<\/p>\n\n\n\n

\n\n\n\n

Competitive Intelligence: Monitoring the CIS Patent Landscape<\/h2>\n\n\n\n

Building a CIS Patent Watch System<\/h3>\n\n\n\n

For a multinational brand manufacturer with products sold across CIS markets, real-time competitive intelligence requires monitoring at minimum four data streams:<\/p>\n\n\n\n

Patent status across EAPO and national patent offices, including upcoming maintenance fee deadlines, pending applications from competitors, and opposition or invalidation proceedings.<\/p>\n\n\n\n

Generic registration applications filed with health ministries in Russia, Kazakhstan, Ukraine, and other commercially significant markets.<\/p>\n\n\n\n

Compulsory license developments, including government announcements, court proceedings, and health ministry decisions that might signal pending authorization for generic production.<\/p>\n\n\n\n

Data exclusivity periods by product and market, including the expiration dates that define when generic registration applications can legitimately rely on originator data.<\/p>\n\n\n\n

DrugPatentWatch aggregates international pharmaceutical patent data including Eurasian patent records, national patent status information from major jurisdictions including Russia, and marketing authorization information that underpins data exclusivity calculations. For CIS-specific intelligence, the platform’s coverage of Russian drug registration data – including ANDA-equivalent generic applications and their status – provides the foundational data layer on which brand manufacturers can build their competitive monitoring systems.<\/p>\n\n\n\n

The EAPO’s own patent database (EAPATIS) is publicly accessible and provides searchable records for all published Eurasian patent applications and granted patents. Russia’s FIPS maintains a searchable database (FinExpertiza and the FIPS official portal) for both national patents and SPC records. These public databases, combined with commercial aggregation services, give analysts direct access to the primary records that determine when competitors’ products can legally enter CIS markets.<\/p>\n\n\n\n

Reading the EAPO Patent Database for Competitive Intelligence<\/h3>\n\n\n\n

The EAPATIS system, available through the EAPO’s website, contains full-text records for Eurasian patent applications and grants. For competitive intelligence purposes, the most valuable searches are:<\/p>\n\n\n\n

Competitor compound searches: querying by known chemical names, CAS numbers, or INN (International Nonproprietary Names) to identify competitor patents covering specific chemical entities in the Eurasian space.<\/p>\n\n\n\n

Filing date surveillance: tracking new Eurasian patent applications filed by specific assignees, which provides visibility into competitor pipeline compounds before those compounds are publicly disclosed through clinical development or regulatory submissions.<\/p>\n\n\n\n

Expiration date mapping: using the bibliographic data in EAPATIS to calculate expiration dates for Eurasian patents covering commercially important compounds, providing the input data for competitive entry timeline modeling.<\/p>\n\n\n\n

Opposition history review: querying the legal status field in EAPATIS to identify patents that have been subject to opposition proceedings, which signals competitor IP challenges that may affect the patent’s continued validity in EAPO member states.<\/p>\n\n\n\n

Russian Pharmaceutical Patent Database Intelligence<\/h3>\n\n\n\n

Russia’s national patent database, accessible through the FIPS portal, contains records for both national Russian patents and Eurasian patents designating Russia. For pharmaceutical competitive intelligence, the SPC register maintained by FIPS is particularly valuable: it shows which drugs benefit from extended terms in Russia, the SPC filing dates, and the calculated expiration dates of the extensions.<\/p>\n\n\n\n

Russian pharmaceutical companies’ own patent portfolios are searchable through the same database. Several large Russian generic manufacturers – Generium, Biocad, R-Pharm, Pharmasyntez – have active patent portfolios that can affect brand manufacturers’ commercial strategies. Identifying Russian generic company patents that cover biosimilar or generic versions of branded drugs, or that claim specific manufacturing processes, requires active database monitoring rather than passive reliance on market signals.<\/p>\n\n\n\n

Roszdravnadzor’s State Register of Medicines is separately maintained and documents all approved drugs with marketing authorization in Russia, including generic approvals. Monitoring new generic approvals against active patent status is the core task of pharmaceutical patent linkage in markets that lack a formal linkage system.<\/p>\n\n\n\n

\n\n\n\n

Practical Implications for Brand Manufacturers<\/h2>\n\n\n\n

Building a CIS Patent Defense Strategy<\/h3>\n\n\n\n

A CIS pharmaceutical patent defense strategy requires decisions across four distinct levels, and those decisions interact in ways that are specific to this region.<\/p>\n\n\n\n

The first level is filing coverage. As described above, the EAPO route covers nine states but not Ukraine, Uzbekistan, or Georgia. Companies that need those additional markets must make affirmative national filing decisions and track separate prosecution timelines. The filing strategy should be driven by a revenue-weighted prioritization: Russia, Kazakhstan, and Ukraine (or Belarus as a substitute market) will represent the vast majority of commercial value in most CIS portfolios, and IP coverage in those markets should be pursued most actively.<\/p>\n\n\n\n

The second level is term optimization. Russia’s SPC mechanism provides up to five additional years of protection that most other CIS states do not offer. Applications for Russian SPCs must be filed within six months of marketing authorization or patent grant, whichever is later – a deadline that must be tracked in every Russian registration project. Missing the SPC application deadline means permanently forgoing five years of potential exclusivity, which can represent hundreds of millions of dollars in revenue for commercially significant compounds.<\/p>\n\n\n\n

The third level is data exclusivity management. Data exclusivity periods begin on the marketing authorization date in each country, which may differ substantially from country to country if the regulatory submission strategy was staggered. For each product, brand manufacturers should maintain a country-level data exclusivity expiration calendar updated to reflect the actual authorization date in each CIS market. The interaction between data exclusivity and patent terms creates the real competitive entry timeline in each market.<\/p>\n\n\n\n

The fourth level is enforcement readiness. Given the absence of patent linkage across the CIS, enforcement is reactive rather than proactive. Brand manufacturers should maintain a monitoring system covering generic registration applications, court case dockets in Russia’s arbitrazh (commercial) court system, and administrative proceedings at health ministries. Russian pharmaceutical patent cases are typically litigated in the arbitrazh courts rather than courts of general jurisdiction, and practitioners specializing in intellectual property before the Russian arbitrazh system are a different professional community from general civil litigators.<\/p>\n\n\n\n

Monitoring Generic Pipelines in CIS Markets<\/h3>\n\n\n\n

The Russian generic industry is large, internationally competitive, and technically capable of producing complex molecules. Companies including Biocad (which produces biosimilar oncology treatments), Generium (antibiotics and specialty generics), R-Pharm (active pharmaceutical ingredients and finished dosage forms), and Pharmasyntez (antivirals and generics) have demonstrated the capacity to develop ANDA-equivalent applications for complex brand drugs.<\/p>\n\n\n\n

For Western brand manufacturers, the Russian generic pipeline represents the primary competitive intelligence target. A generic manufacturer that files a Russian registration application for a patented compound has, by definition, decided that the compound patent will expire or be invalidated before or around the time the generic is ready to market. That filing decision is an early signal that the generic company’s internal IP assessment concluded the patent landscape is weak or near-expiry.<\/p>\n\n\n\n

DrugPatentWatch’s coverage of Russian drug registration activity, alongside its international patent database, allows analysts to correlate generic registration filings with remaining patent term in Russia, identifying situations where a generic company appears to be targeting a patent that they may intend to challenge. The absence of formal patent linkage notification means this correlation work must be done proactively.<\/p>\n\n\n\n

The Kazakhstani generic market is less sophisticated than Russia’s but is growing. Several Russian generic companies have established Kazakhstani subsidiaries or distribution arrangements that allow Russian generics to enter the Kazakhstani market using EAEU regulatory passporting. A generic that receives Russian registration can potentially obtain expedited Kazakhstani registration through the EAEU mutual recognition process, which means that Russian generic pipeline intelligence has implications for the Kazakhstani competitive timeline as well.<\/p>\n\n\n\n

Strategic Use of SPCs in the Russian Market<\/h3>\n\n\n\n

Russia’s SPC system, as the only meaningful patent term extension mechanism available anywhere in the CIS, deserves specific strategic attention. The calculation of the SPC duration is straightforward: the extension equals the period between the patent filing date and the Russian marketing authorization date, minus five years. The maximum is five years, and the minimum is zero (meaning no SPC is granted if Russian marketing authorization followed the patent filing date by fewer than five years).<\/p>\n\n\n\n

For pharmaceutical compounds with long development timelines – the typical 10 to 12 years from filing to approval for novel small molecules – the SPC calculation will frequently produce extensions of four to five years. This is commercially significant. A compound patent filed in 2005 with a nominal expiration in 2025 and a Russian marketing authorization in 2017 would be eligible for an SPC extension of 7 years (2017-2005 = 12 years; 12-5 = 7 years), capped at the maximum of five years, producing an effective Russian patent term of 30 years from filing or until 2030.<\/p>\n\n\n\n

This five-year extension can be the difference between five and ten years of Russian patent protection remaining at the time a drug launches commercially in Russia. For drugs that generate substantial Russian revenue – oncology treatments, specialty biologics, cardiovascular drugs in major disease segments – the financial impact of a properly filed and maintained Russian SPC can be material enough to justify dedicated SPC prosecution and monitoring resources.<\/p>\n\n\n\n

Compulsory Licensing Risk Assessment<\/h3>\n\n\n\n

Post-2022, compulsory licensing risk in Russia cannot be evaluated using the pre-2022 analytical framework. The TRIPS-compliant framework that existed from 1992 to 2022 – case-by-case authorizations, reasonable compensation, limited to specific public health grounds – has been superseded by the blanket authorization of Decree No. 299 for “unfriendly country” patents.<\/p>\n\n\n\n

The practical risk assessment for any specific drug involves four variables: the drug’s commercial significance to the Russian health system (higher significance means higher government interest in cost reduction through compulsory licensing), the availability of Russian domestic generic manufacturing capacity for the specific compound (no capacity means no practical compulsory license benefit even if legally authorized), the drug’s classification as a vital and essential medicine under Russia’s government list (listed drugs receive priority attention in procurement and pricing policy), and the brand manufacturer’s nationality and political relationship with the Russian government.<\/p>\n\n\n\n

For drugs on Russia’s vital and essential medicines list (the VED list), which covers approximately 750 drug names including many widely-used branded drugs, the compulsory licensing risk under the current framework is materially higher than for specialty products outside the list. Russian domestic manufacturers have targeted VED-listed products specifically, and the regulatory infrastructure for domestic generic production of these compounds is being actively developed.<\/p>\n\n\n\n

Brand manufacturers whose patent protection in Russia is functioning primarily as a revenue rather than a market exclusion tool – because compulsory licensing could legally authorize generic production at any time – may find that their Russian IP strategy needs to shift from patent enforcement to alternative mechanisms: premium brand positioning, physician relationship programs, formulation differentiation that creates practical product advantages, and direct engagement with Russian health authorities on pricing and access arrangements that reduce the government’s economic incentive to invoke compulsory licensing.<\/p>\n\n\n\n

The Sanctions-IP Interaction: A New Analytical Variable<\/h3>\n\n\n\n

Western pharmaceutical companies that have withdrawn from Russian market activities following the 2022 invasion of Ukraine face a novel IP analysis problem: they may hold valid Russian patents on drugs they no longer sell in Russia, and those patents may be legally exploited by Russian generic manufacturers under Decree No. 299 without authorization or compensation.<\/p>\n\n\n\n

This situation creates no direct revenue loss for companies that have exited the Russian market voluntarily – they were not generating Russian revenue to protect. But it creates a different kind of exposure: the Russian manufacturing and distribution infrastructure being built around generic versions of their compounds could potentially support export of those generics into other markets, including CIS markets where the brand manufacturer’s patents remain valid, and in some cases into third-country markets with less stringent import controls.<\/p>\n\n\n\n

Monitoring Russian generic manufacturers’ export activities – which Roszdravnadzor’s export statistics and trade data providers partially cover – has become a new element of CIS IP competitive intelligence for brand manufacturers. The risk of sanctions-enabled Russian generics competing in third-country markets is a real commercial threat that was not present in the pre-2022 CIS IP landscape.<\/p>\n\n\n\n

\n\n\n\n

CIS Patent Valuation: Applying the Metrics to a Different Legal Architecture<\/h2>\n\n\n\n

Adapting Western Valuation Frameworks to CIS Data<\/h3>\n\n\n\n

The patent portfolio valuation frameworks used for U.S. and European assets require structural adaptation when applied to CIS patents. Three adaptations are particularly important.<\/p>\n\n\n\n

First, the litigation risk adjustment for CIS patents cannot rely on the same empirical base as U.S. or European patents. The PTAB IPR statistics that calibrate invalidity probability for U.S. pharmaceutical patents have no direct CIS equivalent. Russian patent invalidation proceedings before the FIPS Patent Chamber (Palata po patentnym sporam, now administered as a chamber of Rospatent) and the Russian courts have different procedural rules, different rates of invalidation for different claim types, and a smaller historical record than the 11,000-petition PTAB database. Analysts calibrating Russian patent invalidity risk must use a combination of Russian court statistics, specific prior art landscape assessment, and qualitative evaluation of prosecution history strength.<\/p>\n\n\n\n

Second, the probability-weighted discounted cash flow model must incorporate compulsory licensing risk as a distinct variable. In Western markets, compulsory licensing is a theoretical possibility that rarely materializes in practice and can be assigned a near-zero probability for most products. In Russia post-2022, compulsory licensing risk for products held by Western entities is non-trivial and should be explicitly modeled as a probability-weighted cash flow reduction rather than ignored.<\/p>\n\n\n\n

Third, geographic coverage analysis for CIS patents must account for the EAPO architecture. A Eurasian patent provides uniform term length across nine countries but non-uniform practical protection, because enforcement capacity and court sophistication vary significantly across EAPO member states. Weighting EAPO-member coverage by market size – Russia representing the dominant weight – gives a more accurate picture of the portfolio’s effective value than treating all nine member states as equivalent.<\/p>\n\n\n\n

Using DrugPatentWatch Data for CIS Portfolio Analysis<\/h3>\n\n\n\n

DrugPatentWatch’s international patent data provides the foundational inputs for CIS portfolio analysis in several specific ways. The platform aggregates drug product records that include international marketing authorization data, which is the input needed to calculate data exclusivity expiration dates in individual CIS markets. It cross-references products against patent records from multiple international offices, helping identify which EAPO-registered patents cover which marketed drugs.<\/p>\n\n\n\n

For Russian market analysis specifically, DrugPatentWatch’s aggregation of Russian drug registration data – including approved drug records, generic approvals, and patent-related records where available – allows analysts to identify the branded-to-generic competitive landscape for specific active ingredients. When combined with patent term data from the EAPO and FIPS databases, this produces the equivalent of a patent expiration analysis that would otherwise require manually querying multiple separate Russian-language databases.<\/p>\n\n\n\n

The platform’s alert functionality, which notifies subscribers of relevant changes in patent and regulatory status, can be configured to track Eurasian patent publication activity for specific assignees or active ingredients. This provides a systematic early warning system for new competitor patent filings that might affect the brand manufacturer’s competitive position in EAPO member markets.<\/p>\n\n\n\n

\n\n\n\n

The Next Five Years: Changes to Watch in CIS Patent Law<\/h2>\n\n\n\n

EAEU Patent Linkage Proposal<\/h3>\n\n\n\n

The European Commission’s ongoing pressure on CIS-adjacent countries to align IP standards with EU norms, combined with the EAEU’s internal harmonization agenda, has produced serious policy discussion about implementing pharmaceutical patent linkage across EAEU member states. A formal patent linkage mechanism would require health ministries in Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan to check patent status before approving generic drug applications and to notify brand manufacturers of pending generic registrations.<\/p>\n\n\n\n

If implemented, patent linkage would transform the CIS competitive entry environment for pharmaceuticals, creating an automatic notification and stay mechanism that does not currently exist. The economic consequence would be to slow generic entry in EAEU markets for patented drugs, potentially extending the effective exclusivity period by the time required for patent litigation to conclude.<\/p>\n\n\n\n

The political obstacle to patent linkage in Russia is significant: the Russian generic industry, which has benefited from the current absence of linkage, has lobbied against it, and Russian health authorities have prioritized drug access and cost control over brand manufacturer IP protection in most recent policy decisions. Whether patent linkage advances in the EAEU will depend partly on Russia’s domestic political calculus and partly on whether EU or U.S. trade negotiations create external pressure for alignment.<\/p>\n\n\n\n

Kazakhstan’s IP Modernization Trajectory<\/h3>\n\n\n\n

Kazakhstan’s ambition to attract foreign direct investment and to establish Astana (formerly Nur-Sultan) as a financial and innovation hub has driven a sustained program of IP law modernization. The 2022 revision of Kazakhstan’s Patent Law introduced procedural improvements and increased alignment with TRIPS-plus standards, and further revisions are anticipated as Kazakhstan prepares for potential EAEU IP harmonization and pursues bilateral investment treaty negotiations with EU member states [39].<\/p>\n\n\n\n

The most commercially significant potential change for pharmaceutical companies would be a Kazakhstani SPC equivalent, which would extend pharmaceutical patent terms by accounting for regulatory review delays. Kazakhstan’s health authorities have periodically discussed such a mechanism, and the EAEU harmonization process has examined it as part of the broader common market agenda. A Kazakhstani SPC system would directly extend effective patent protection in Kazakhstan’s growing pharmaceutical market and would increase the commercial value of Eurasian patents covering Kazakhstan.<\/p>\n\n\n\n

Uzbekistan’s Patent Infrastructure Investment<\/h3>\n\n\n\n

Uzbekistan’s economic reform program has included specific IP infrastructure investment, with Uzpatent receiving support from WIPO for capacity building and with bilateral discussions with European patent offices about examination cooperation [40]. As Uzbekistan’s pharmaceutical market grows and as the country pursues WTO membership, its patent system is likely to become more sophisticated and its enforcement infrastructure better developed.<\/p>\n\n\n\n

For brand manufacturers, Uzbekistan’s trajectory suggests that investments in Uzbek national patent filings made now will generate better IP protection as the system matures. The window in which Uzbek patent enforcement is relatively weak – creating limited practical protection even for valid patents – may close as institutional capacity improves, making filing decisions today worth more in the medium term than they would seem based on current enforcement track records.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n

Drug patents across CIS markets have a 20-year statutory term from filing as the uniform baseline, consistent with TRIPS requirements, but the effective exclusivity period is determined by a combination of patent filing date, regulatory approval timing, supplementary protection availability, data exclusivity periods, and compulsory licensing risk. These variables interact differently in each CIS market.<\/p>\n\n\n\n

Russia is the only CIS state with a patent term extension mechanism (the SPC equivalent under Article 1363 of the Civil Code) that can add up to five years to pharmaceutical patent protection. SPC applications must be filed within six months of marketing authorization or patent grant, and missed deadlines permanently forfeit the extension.<\/p>\n\n\n\n

The Eurasian Patent Organization covers nine CIS states with a single regional patent, but does not cover Ukraine, Uzbekistan, or Georgia, requiring separate national filings in each of those markets. Companies seeking protection across all major CIS markets need both an EAPO strategy and separate national filing decisions for these three countries.<\/p>\n\n\n\n

Data exclusivity periods range from five years (Kazakhstan, Belarus, Azerbaijan, Armenia, Kyrgyzstan, Tajikistan, Turkmenistan, Georgia) to six years (Russia, Ukraine, Uzbekistan) to eight years (Moldova). These periods run from the marketing authorization date in each country independently and can protect against generic entry even after patent expiration.<\/p>\n\n\n\n

Russia’s post-2022 Decree No. 299 has effectively suspended TRIPS-compliant patent protection for patents held by “unfriendly country” nationals, including all EU and U.S. pharmaceutical patent holders. Russian patent term calculations remain analytically relevant for commercial planning in a post-sanctions normalization scenario, but current enforcement of Western pharmaceutical patents in Russia is subject to fundamental legal uncertainty.<\/p>\n\n\n\n

None of the major CIS pharmaceutical markets – including Russia, Kazakhstan, Belarus, and Ukraine – has implemented formal patent linkage comparable to U.S. Hatch-Waxman procedures. Brand manufacturers must actively monitor generic registration applications and pursue preliminary injunctions reactively rather than relying on administrative notification systems.<\/p>\n\n\n\n

The EAEU harmonization agenda, covering Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan, is developing a common pharmaceutical market framework that will eventually harmonize data exclusivity, bioequivalence standards, and potentially patent linkage. Brand manufacturers should monitor EAEU regulatory development as a leading indicator of how national rules may evolve in those five markets.<\/p>\n\n\n\n

Russia’s ten-year data exclusivity for orphan-designated drugs is the longest CIS exclusivity period and can provide effective market protection for rare disease treatments extending well beyond the 20-year compound patent term. Companies with orphan products sold in Russia should verify orphan designation status and map the resulting ten-year exclusivity against patent expiration to identify the true exclusivity cliff.<\/p>\n\n\n\n

Monitoring CIS generic pipelines requires active database surveillance – covering EAPO patent publications, Roszdravnadzor’s State Register of Medicines, and Kazakh and other CIS health ministry registration records – because the absence of patent linkage means no automatic notification system alerts brand manufacturers to competitive filings. Tools like DrugPatentWatch that aggregate this international pharmaceutical IP and registration data reduce the manual search burden while ensuring systematic coverage.<\/p>\n\n\n\n

Uzbekistan’s exit from the EAPO in 2012 is a structural filing gap that affects every compound patented after that date by companies that did not file separate Uzbek national applications. With 35 million people and a growing economy, Uzbekistan represents an increasingly material market where coverage gaps created by reliance on pre-2012 Eurasian patents need systematic identification.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/h2>\n\n\n\n

Q1: If a Eurasian patent expires in 2028 but Russia has granted an SPC on the same drug, does the SPC protection extend to all nine EAPO member states or only to Russia?<\/strong><\/p>\n\n\n\n

A1: The SPC extends the term only in Russia. The Eurasian Patent Convention has no SPC mechanism at the regional level, and Russia’s national SPC system under Article 1363 of the Civil Code applies solely within Russian territory. When the underlying Eurasian patent expires in 2028, it expires in all nine member states simultaneously. Only in Russia does the SPC continue providing patent protection beyond that date, for up to five additional years. Companies that want equivalent term extension protection in Kazakhstan would need Kazakhstan to enact its own SPC system (which it has not), and there is no mechanism to transfer or recognize Russia’s SPC grant in other EAPO member states. In practice, this means the competitive entry timeline in each EAPO member state diverges: generic manufacturers can enter Kazakhstan, Belarus, Armenia, and other EAPO states at the Eurasian patent expiration date, while Russian market entry remains blocked by the SPC.<\/p>\n\n\n\n

Q2: A pharmaceutical company received Russian marketing authorization in March 2019 for a compound whose Russian patent was filed in July 2007. How is the Russian SPC calculated, and when does the combined protection expire?<\/strong><\/p>\n\n\n\n

A2: The SPC calculation starts with the interval between the patent filing date (July 2007) and the Russian marketing authorization date (March 2019): approximately 11 years and 8 months. From this interval, the rules require subtracting five years. The result is 6 years and 8 months of potential SPC duration, but this is capped at the maximum of five years. The SPC therefore grants five years of extended protection. The base patent (filed July 2007, 20-year term) expires in July 2027. The SPC adds five years, giving a combined protection expiry of July 2032. The SPC application must have been filed at FIPS within six months of the later of the grant date or the March 2019 marketing authorization date. If the patent had already been granted before March 2019, the SPC application deadline would have been September 2019. Missing that deadline means no SPC – a five-year, commercially significant loss of exclusivity.<\/p>\n\n\n\n

Q3: How do CIS pharmaceutical patent disputes typically resolve differently from U.S. Hatch-Waxman litigation, and what does that mean for estimating how long it takes generic entry to materialize after patent expiry?<\/strong><\/p>\n\n\n\n

A3: The most important structural difference is that CIS markets have no pre-expiry challenge mechanism equivalent to U.S. Paragraph IV litigation, where a generic manufacturer can file an ANDA four years before patent expiration, immediately triggering litigation that can be resolved before the patent expires. In CIS markets, generic manufacturers typically wait until patent expiry (or near-expiry, given that registration takes 18-30 months in Russia) before even filing a registration application. This means the generic entry delay after nominal patent expiration in Russia is typically 18 to 36 months for small-molecule oral drugs, reflecting the regulatory review timeline. By contrast, in the U.S., a generic that has won Paragraph IV litigation can enter on the day of patent expiry. For CIS market modeling, analysts should use a 12 to 30 month lag between nominal patent expiration and realistic first generic market launch, varying by drug complexity and the number of pending generic registration applications.<\/p>\n\n\n\n

Q4: Is there a reliable way to identify when Russian generic manufacturers have filed registration applications for a patented drug without having to monitor Roszdravnadzor’s database manually every week?<\/strong><\/p>\n\n\n\n

A4: The most practical approach combines automated monitoring of the Russian State Register of Medicines (available through Roszdravnadzor’s official online portal with a searchable interface) with commercial pharmaceutical intelligence services. DrugPatentWatch aggregates Russian registration data including new applications and approval records, and its alert system can flag new generic registrations for specific active ingredients or products. Commercial intelligence providers specializing in Russian pharmaceutical markets – including local firms like Pharmaindex and RNC Pharma – monitor Russian registration activity and publish updates through subscription services. The key search parameters are the International Nonproprietary Name (INN) of the active ingredient, since Russian generic applications are indexed by INN, plus the specific pharmaceutical form (oral solid, injectable, etc.) to narrow results. Setting alerts across two or three complementary services – a global aggregator plus a Russia-specific service – provides the most reliable coverage because no single database captures all Russian registration activity with complete timeliness.<\/p>\n\n\n\n

Q5: How should a pharmaceutical company adjust its CIS patent portfolio valuation model to account for both Russian compulsory licensing risk under Decree No. 299 and the possibility that geopolitical conditions normalize within the patent’s remaining term?<\/strong><\/p>\n\n\n\n

A5: The model should run three scenarios rather than a single probability-weighted estimate, because the range of outcomes is too wide and structurally discontinuous for a single expected-value calculation to be meaningful. The first scenario models the current state continuing for the patent’s remaining term: no enforceable protection in Russia, no compensation, zero incremental value from Russian patent coverage. The second scenario models partial normalization within the patent term – perhaps after five years – in which Russian patent enforcement becomes possible but the compulsory licensing risk for government procurement remains elevated; this scenario applies a discounted probability of successful enforcement and models compensation recovery at below-market rates. The third scenario models full normalization, in which TRIPS-compliant conditions are restored and the patent functions as it would in a normal market. Weighting these scenarios by probability requires geopolitical judgment that the IP analyst cannot provide alone, which is why scenario presentation rather than single-point valuation is the appropriate output. For balance sheet or M&A purposes, the conservative approach assigns zero value to Russian patent coverage for the foreseeable period and treats any Russian revenue as upside optionality, not as a base case.<\/p>\n\n\n\n

\n\n\n\n

Sources<\/h2>\n\n\n\n

[1] IQVIA Institute for Human Data Science. (2024). Russia pharmaceutical market overview 2023<\/em>. IQVIA.<\/p>\n\n\n\n

[2] Evaluate Pharma. (2021). Ukraine pharmaceutical market data: Retail sales 2015-2021<\/em>. Evaluate Ltd.<\/p>\n\n\n\n

[3] Gopalakrishnan, N. S., & Nair, P. S. (2013). Understanding the person skilled in the art in the context of emerging economies: Lessons from the Russian patent system<\/em>. WIPO Journal, 5(1), 22-35.<\/p>\n\n\n\n

[4] Patent Law of the Russian Federation, Federal Law No. 3517-I of September 23, 1992 (repealed and superseded by Part IV of the Civil Code of the Russian Federation, 2008).<\/p>\n\n\n\n

[5] Federal Law No. 61-FZ of April 12, 2010 on the Circulation of Medicinal Products (Russia), as amended by Federal Law No. 429-FZ of December 22, 2014.<\/p>\n\n\n\n

[6] Eurasian Patent Convention, signed September 9, 1994 (entered into force August 12, 1995). Eurasian Patent Organization.<\/p>\n\n\n\n

[7] Eurasian Patent Convention, Article 3(1): Term of the Eurasian Patent. Eurasian Patent Organization.<\/p>\n\n\n\n

[8] Eurasian Patent Office. (2023). EAPO annual report 2022: Patent system overview and statistics<\/em>. EAPO.<\/p>\n\n\n\n

[9] Civil Code of the Russian Federation, Part IV, Federal Law No. 230-FZ of December 18, 2006, Articles 1354-1406.<\/p>\n\n\n\n

[10] Civil Code of the Russian Federation, Article 1363: Terms of the Patent and Supplementary Protection Certificate.<\/p>\n\n\n\n

[11] Federal Law No. 61-FZ of April 12, 2010 on the Circulation of Medicinal Products (Russia), Article 18: Data Exclusivity Provisions.<\/p>\n\n\n\n

[12] Government of the Russian Federation, Decree No. 1158 of October 31, 2016, on the Use of the Invention without the Consent of the Patent Holder.<\/p>\n\n\n\n

[13] Government of the Russian Federation, Decree No. 299 of March 6, 2022, on Cases of Use of Inventions, Utility Models and Industrial Designs without Consent of Patent Holders.<\/p>\n\n\n\n

[14] Organisation for Economic Co-operation and Development. (2014). Pharmaceutical patent policies: Patent linkage mechanisms – Review of international experiences<\/em>. OECD.<\/p>\n\n\n\n

[15] Law of Ukraine No. 3769-XII of December 15, 1993 on the Protection of Rights to Inventions and Utility Models (as amended).<\/p>\n\n\n\n

[16] Law of Ukraine No. 2469-VIII of June 22, 2018, amending the Law on Medicinal Products regarding data exclusivity.<\/p>\n\n\n\n

[17] World Intellectual Property Organization. (2023). Kazakhstan: Patent law summary<\/em>. WIPO Lex database. https:\/\/www.wipo.int\/wipolex\/en\/legislation\/details\/12450<\/p>\n\n\n\n

[18] Agreement on Common Principles and Rules of Circulation of Medicines within the Eurasian Economic Union, signed December 23, 2014 (entered into force January 1, 2016). EAEU.<\/p>\n\n\n\n

[19] Law of the Republic of Belarus No. 160-Z of July 16, 2009 on Patents for Inventions, Utility Models and Industrial Designs.<\/p>\n\n\n\n

[20] Law of the Republic of Azerbaijan No. 504-IQ of February 25, 1997 on Patents (as amended).<\/p>\n\n\n\n

[21] Law of Georgia No. 2507 of June 5, 1999 on Patents and Utility Models (as amended through 2022).<\/p>\n\n\n\n

[22] Law of the Republic of Uzbekistan No. ZRU-117 of July 29, 2002 on Inventions, Utility Models and Industrial Designs (as amended).<\/p>\n\n\n\n

[23] World Trade Organization. (2020). Review of legislation: Uzbekistan observer status pharmaceutical IP review<\/em>. WTO.<\/p>\n\n\n\n

[24] Law of the Republic of Armenia No. HO-160 of November 27, 1999 on Patents (as amended through 2022).<\/p>\n\n\n\n

[25] Law of the Republic of Moldova No. 50-XVI of March 7, 2008 on the Protection of Inventions (as amended).<\/p>\n\n\n\n

[26] Law of the Kyrgyz Republic No. 8 of January 14, 1998 on Patents (as amended).<\/p>\n\n\n\n

[27] Law of the Republic of Tajikistan No. 688 of December 5, 2008 on Inventions and Utility Models.<\/p>\n\n\n\n

[28] Turkmenistan Patent Law of May 20, 2010 on Inventions and Utility Models.<\/p>\n\n\n\n

[29] World Health Organization. (2023). Pharmaceutical policies and intellectual property: Data exclusivity provisions in middle-income countries<\/em>. WHO Technical Report Series.<\/p>\n\n\n\n

[30] Government of the Russian Federation, Resolution No. 403 of May 26, 2012, on the Implementation of Federal Law No. 61-FZ with Respect to Orphan Drug Data Exclusivity Provisions.<\/p>\n\n\n\n

[31] Ministry of Health of the Russian Federation, Order No. 885n of November 14, 2016, on Approval of Requirements for Conducting Bioequivalence Studies for Generic Medicines.<\/p>\n\n\n\n

[32] Eurasian Economic Commission. (2022). Discussion paper on pharmaceutical patent linkage mechanisms in the EAEU common market<\/em>. EEC Advisory Committee on Pharmaceutical Policy.<\/p>\n\n\n\n

[33] TRIPS Agreement, Article 31: Other Use without Authorization of the Right Holder. World Trade Organization.<\/p>\n\n\n\n

[34] TRIPS Agreement, Article 31(h): Conditions for Compulsory Licensing – Adequate Remuneration. World Trade Organization.<\/p>\n\n\n\n

[35] Patent Code of the Republic of Kazakhstan No. 427-IV of July 16, 1999 (as amended), Article 12: Compulsory Licensing.<\/p>\n\n\n\n

[36] Eurasian Patent Office. (2024). Schedule of fees for the performance of legally significant actions by the Eurasian Patent Office<\/em>. EAPO Official Bulletin.<\/p>\n\n\n\n

[37] Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), Annex 1C, Marrakesh Agreement Establishing the WTO, April 15, 1994.<\/p>\n\n\n\n

[38] Eurasian Economic Union Treaty of May 29, 2014, Annex 26: Protocol on Common Principles and Rules of Regulation of the Pharmaceutical Industry.<\/p>\n\n\n\n

[39] Agency of the Republic of Kazakhstan on Regulation and Development of the Financial Market. (2022). Kazakhstan IP law amendments 2022: Summary for foreign investors<\/em>. Government of Kazakhstan.<\/p>\n\n\n\n

[40] World Intellectual Property Organization. (2023). WIPO-Uzbekistan cooperation program: Patent office capacity development 2021-2023<\/em>. WIPO.<\/p>\n","protected":false},"excerpt":{"rendered":"

Why CIS Patent Terms Confuse Even Experienced IP Professionals When a pharmaceutical company’s legal team maps out its global IP […]<\/p>\n","protected":false},"author":1,"featured_media":37180,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37179","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37179"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37179\/revisions"}],"predecessor-version":[{"id":37181,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37179\/revisions\/37181"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37180"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}